AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 204.89B +25.9% |
| Revenue (ttm) | 45.77B +9.9% |
| Net Income | 7.87B +33.7% |
| EPS | 5.03 +33.6% |
| Shares Out | 1.55B |
| PE Ratio | 26.27 |
| Forward PE | 16.70 |
| Dividend | 2.36 (1.79%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 1,981,601 |
| Open | 11,232 |
| Previous Close | 13,214 |
| Day's Range | 11,232 - 13,210 |
| 52-Week Range | 101 - 13,210 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 16,475.14 (+24.72%) |
| Earnings Date | Jul 27, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 16,475p, which is an increase of 24.72% from the latest price.
News
AstraZeneca (AZN) Benefits from New FDA Guidance on Gene Therapy Development
AstraZeneca (AZN) Benefits from New FDA Guidance on Gene Therapy Development
AstraZeneca's Camizestrant Shows Strong Results in Phase III Trial (AZN)
AstraZeneca's Camizestrant Shows Strong Results in Phase III Trial (AZN)
AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant
AstraZeneca (AZN) Reports Promising Phase III Trial Results for Camizestrant
AstraZeneca announces additional results from Phase III Serena-6 trial
Further positive results from the Phase III Serena-6 trial showed AstraZeneca’s (AZN) camizestrant plus a cyclin-dependent kinase, CDK, 4/6 inhibitor – palbociclib, ribociclib or abemaciclib – maintai...
AstraZeneca reports ‘further positive results’ from Phase 3 SERENA-6 trial
Further positive results from the Phase III SERENA-6 trial showed AstraZeneca’s (AZN) camizestrant plus a cyclin-dependent kinase 4/6 inhibitor – palbociclib, ribociclib or abemaciclib – maintained it...
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
WILMINGTON, Del.--(BUSINESS WIRE)--Further positive results from the Phase III SERENA-6 trial showed AstraZeneca's camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor – palbociclib, riboci...
AstraZeneca PLC (AZN) Stock Down 3.2% but Still Overvalued -- GF Score: 84/100
AstraZeneca PLC (AZN) Stock Down 3.2% but Still Overvalued -- GF Score: 84/100
5 Foreign Stocks That Could Beat The S&P 500
James Demmert explains why foreign markets are beating the U.S.—and the five international stocks he thinks can outperform the S&P 500.
AstraZeneca (AZN) Reports Positive Results in Phase III Trial for HCC Treatment
AstraZeneca (AZN) Reports Positive Results in Phase III Trial for HCC Treatment
AstraZeneca announces reuslts from EMERALD-3 Phase III trial of Imfinzi
Positive results from the EMERALD-3 Phase III trial showed AstraZeneca’s (AZN) Imfinzi in combination with Imjudo, lenvatinib and transarterial chemoembolization, TACE, demonstrated a statistically si...
AstraZeneca Scores In Liver Cancer On Its Path To $40 Billion In Oncology Sales
AstraZeneca added to its Imfinzi armamentarium on Monday after the immuno-oncology drug led to improved survival in liver cancer patients.
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the EMERALD-3 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and transa...
AstraZeneca Transcript: Investor update
Significant pipeline progress includes approvals for new molecular entities and robust phase III momentum. EMERALD-3 demonstrated strong PFS and OS trends in liver cancer, supporting blockbuster potential. Oncology assets, including ADCs and bispecifics, are driving innovation and commercial growth.
AstraZeneca Slides: Investor update
AstraZeneca has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology
LUND, SE / ACCESS Newswire / June 1, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it w...
Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart
NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple the...
Anselamimab Shows Promise in Phase 3 Trials for AL Amyloidosis (AZN)
Anselamimab Shows Promise in Phase 3 Trials for AL Amyloidosis (AZN)
AstraZeneca says CARES Phase 3 clinical program did not meet primary endpoint
The company states: “The global CARES Phase 3 clinical programme showed that treatment with anselamimab, a potential first-in-class anti-fibril therapy, resulted in nominally statistically significant...
AstraZeneca (AZN) Gains Approval for Imfinzi in Bladder Cancer Treatment
AstraZeneca (AZN) Gains Approval for Imfinzi in Bladder Cancer Treatment
AstraZeneca Imfinzi combination approved in the U.S.
AstraZeneca’s (AZN) Imfinzi in combination with Bacillus Calmette-Guerin induction and maintenance therapy has been approved in the U.S. for the treatment of adult patients with BCG-naive, high-risk n...
FDA Approves IMFINZI Combination With BCG For Non-muscle-invasive Bladder Cancer In Adults
(RTTNews) - AstraZeneca PLC (AZN, AZN.L, ZEG.DE, AZN.ST) announced that its IMFINZI (durvalumab), in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy, has been approve...
AstraZeneca’s durvalumab approved in U.S. for NMIBC patients
The company states: “AstraZeneca’s (AZN) IMFINZI – or durvalumab – in combination with Bacillus Calmette-Guerin – BCG – induction and maintenance therapy has been approved in the US for the…
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatmen...
IMFINZI (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
AstraZeneca’s IMFINZI (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve, ...
AstraZeneca (AZN) Receives FDA Approval for Imfinzi in Bladder Cancer Treatment
AstraZeneca (AZN) Receives FDA Approval for Imfinzi in Bladder Cancer Treatment